证券代码：605199 证券简称：葫芦娃 公告编号：2023-043 海南葫芦娃药业集团股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日以电子邮件方式发出第三届董事会第二次会议通知，会议于 2023 年 8 月 28 日在海南省海口市国家高新区药谷工业园二期药谷四路 8 号会议室以 现场结合通讯方式召开会议，应参加表决的董事 7 人，实际参加表决的董 事 7 人，公司全体监事、高级管理人员列席会议，本次董事会会议由董事长 刘景萍女士主持。本次会议的召集、召开和表决程序符合有关法律、法规和 《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 具体内容详见同日于上海证券交易所网站（www.sse.com.cn）披露的公 告。 表决结果：7 票同意，0 票反对，0 票弃权。 （二）审议通过了《关于 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2023-045 海南葫芦娃药业集团股份有限公司 第三届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）审议通过《关于公司 2023 年半年度募集资金存放与实际使用情 况专项报告的议案》 监事会认为：公司 2023 年半年度募集资金的存放与使用情况符合中国 证监会、上海证券交易所关于上市公司募集资金存放和使用的相关规定，亦 符合公司《募集资金管理办法》的有关规定，不存在募集资金存放与使用违 规的情形。 表决结果：同意 3 票，弃权 0 票，反对 0 票。 一、 监事会会议召开情况 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日以电子邮件方式发出第三届监事会第二次会议通知，会议于 2023 年 8 月 28 日在海南省海口市国家高新区药谷工业园药谷二期四路 8 号会议 室以现场方式召开会议，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事会主席徐鹏主持。本次会议的召集、召开和表决程序符 合 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2023-041 海南葫芦娃药业集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收 到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于 布立西坦注射液的《药物临床试验批准通知书》，同意本品开展临床 试验。现将有关情况公告如下： 二、药品研发及相关情况 布立西坦注射液是公司开发用于辅助抗癫痫治疗用药，为化药 3 类。本品拟定适应症为：本品用于成人、青少年和 2 岁以上儿童部分 性癫痫发作，伴或不伴继发性全身性发作的辅助治疗。口服制剂暂不 可行时的替代给药。 布立西坦由比利时优时比制药公司（UCB Pharma） 研制，分别于 2016 年 1 月 14 日和 2016 年 2 月 18 日经欧洲医药管理局（EMA） 和美国食品药品管理局（FDA） 批准上市，用于治疗 16 岁及以上部 分性发作型的癫痫患者，伴有或不伴随继发全身性发作的辅助治疗药， 商品名为 B ...

证券代码：605199 证券简称：葫芦娃 公告编号：2023-042 海南葫芦娃药业集团股份有限公司 关于向不特定对象发行可转换公司债券申请收到上海证券 交易所审核问询函的公告 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日收到 上海证券交易所（以下简称"上交所"）出具的《关于海南葫芦娃药业集团股份有限公 司向不特定对象发行可转换公司债券申请文件的审核问询函》（上证上审（再融资） 〔2023〕599 号），上交所审核机构对公司向不特定对象发行可转换公司债券申请文件进 行了审核，并形成了首轮问询问题。 公司将与相关中介机构按照上述问询函的要求，对相关问题进行逐项落实并提交回 复，回复内容将及时披露，并通过上交所发行上市审核业务系统报送相关文件。公司本 次向不特定对象发行可转换公司债券事项尚需通过上交所审核，并获得中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施，最终能否通过 上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确定性。公司将根据 该事项的进展情况，严格按照相关法律法规和要求及时履行信息披露义务，敬请广大投 资者注意投资风险 ...

上海证券交易所文件 上证上审（再融资）〔2023〕599 号 关于海南葫芦娃药业集团股份有限公司向不 特定对象发行可转换公司债券申请文件的审 核问询函 海南葫芦娃药业集团股份有限公司、中信建投证券股份有限公司： 根据《证券法》《上市公司证券发行注册管理办法》《上海证 券交易所上市公司证券发行上市审核规则》等有关法律、法规及 本所有关规定等，本所审核机构对海南葫芦娃药业集团股份有限 公司（以下简称发行人或公司）向不特定对象发行可转换公司债 券申请文件进行了审核，并形成了首轮问询问题。 1.关于本次募投项目必要性 根据申报材料，1）公司本次募投项目包括"南宁生产基地二 期项目"、"数字化建设项目"等。"南宁生产基地二期项目"拟生产 的药品主要包括复方甘草口服溶液等已有产品，拟生产药品的注 ─────────────── 册批件有效期均为 2025 年 9 月。该项目预计建设期为三年。"数 字化建设项目"拟通过购置、升级相关软硬件设备，完善现有信 息化体系。2）公司曾于 2021 年申请非公开发行股票募集资金 10 亿元，但最终未发行，发行批文到期失效。前次非公开发行募投 项目之一为"南宁生产基地二期项目"，与本次 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2023-040 海南葫芦娃药业集团股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）上述担保的内部决策程序 1 一、担保情况概述 （一）担保的基本情况 2023年4月17日，公司召开第三届董事会第一次会议，审议通过了《关于公司及子公 司和孙公司向金融机构申请2023年度综合授信额度及提供相应担保额度预计的议案》， 独立董事对该事项均发表了同意的独立意见。2023年5月12日，公司召开了2022年度股 东大会，审议通过了《关于公司及子公司和孙公司向金融机构申请2023年度综合授信额 为满足广西维威生产经营的需要，广西维威拟向招商银行股份有限公司南宁分行申 请授信，公司为其提供连带责任保证担保，担保的债权最高额限度为人民币5,000 万元 和相应的利息、罚息、复息、违约金、迟延履行金、保理费用、实现担保权和债权的费 用和其他相关费用。 被担保人名称及是否为上市公司关联人：广西维威制药有限公司（以下简称"广 西维威 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让 投资者更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司 透明度和治理水平，海南证监局将与深圳市全景网络有限公司、海南上市公 司协会联合举办"海南辖区投资者网上集体接待日暨上市公司业绩说明会" 活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为： http://rs.p5w.net。 届时，公司主要高管人员将参加本次活动，通过网络在线交流形式， 就公司 2022 年年报披露、财务数据、公司治理、内部控制、发展战略、经 营状况、现金分红、重大事项、可持续发展等投资者所关心的问题，与投资 者进行"一对多"形式的沟通与交流。欢迎广大投资者踊跃参与。 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2023 年 5 月 17 日 证券代码：605199 证券简称：葫芦娃 公告编号：2023-031 海南葫芦娃药业集团股份有限公司 关于参加"2022 年度海南辖区上市公司业 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2023-029 海南葫芦娃药业集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨 现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 10 日(星期三) 上午 10:00-11:30 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.c om/）、价值在线（www.ir-online.cn） 会议召开方式：视频录播和网络互动 投资者可于 2023 年 04 月 28 日(星期五) 至 05 月 09 日(星期二)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hnhlwyyjtgf@163.c om 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发 布公司 2022 年度报告和 2023 年第一季度报告 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥527,261,635.05, representing a year-on-year increase of 32.09%[5] - The net profit attributable to shareholders for the same period was ¥40,560,003.62, reflecting a growth of 35.59% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.10, an increase of 42.86% year-on-year[6] - Total operating revenue for Q1 2023 was CNY 527.26 million, an increase from CNY 399.17 million in Q1 2022, representing a growth of approximately 32.2%[20] - Net profit for Q1 2023 reached CNY 40.42 million, compared to CNY 29.89 million in Q1 2022, reflecting a growth of approximately 35.2%[22] - Earnings per share for Q1 2023 were CNY 0.10, an increase from CNY 0.07 in Q1 2022[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,352,978,170.87, which is a 1.77% increase from the end of the previous year[6] - Total assets as of March 31, 2023, are ¥2,352,978,170.87, compared to ¥2,312,057,375.26 at the end of 2022[18] - The total liabilities as of Q1 2023 amounted to CNY 1,297.29 million, slightly up from CNY 1,296.79 million in the previous year[21] - Total current liabilities decreased to ¥868,961,259.33 from ¥1,056,887,876.28 year-over-year[18] - The company reported a significant reduction in short-term borrowings, which decreased to ¥418,286,060.53 from ¥500,950,785.99[18] Cash Flow - The cash flow from operating activities showed a net outflow of ¥118,334,967.44, which is not applicable for year-on-year comparison[5] - Cash flow from operating activities in Q1 2023 was a net outflow of CNY 118.33 million, compared to a net outflow of CNY 110.76 million in Q1 2022[23] - The net cash flow from investing activities was -123,101,426.17, compared to -74,481,823.60 in the previous period, indicating a significant increase in cash outflow for investments[24] - Cash inflow from financing activities amounted to 257,345,765.82, a substantial increase from 52,214,400.00 in the prior period, reflecting enhanced borrowing activities[24] - The net increase in cash and cash equivalents was -141,230,543.14, compared to -280,489,455.93 in the previous period, indicating an improvement in cash flow management[24] Expenses - The company's management expenses rose by 52.50%, primarily due to increased labor costs and intermediary service fees[11] - Total operating costs for Q1 2023 were CNY 467.07 million, up from CNY 358.18 million in Q1 2022, indicating an increase of about 30.4%[21] - Research and development expenses for Q1 2023 were CNY 19.60 million, down from CNY 34.79 million in Q1 2022, indicating a decrease of approximately 43.7%[21] - Sales expenses for Q1 2023 were CNY 169.48 million, compared to CNY 158.33 million in Q1 2022, showing an increase of about 7.3%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,753[14] - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 167,079,000 shares, accounting for 41.7% of total shares[14] Inventory and Accounts - The company's inventory increased by 48.02% due to the need to stock up on raw materials and auxiliary materials for production[11] - Accounts receivable increased to ¥392,731,683.05 from ¥312,492,879.36 year-over-year[17] - Inventory as of March 31, 2023, is ¥316,102,153.81, up from ¥213,560,704.28 at the end of 2022[17] - The company reported a significant increase of 126.05% in accounts payable, attributed to higher procurement costs due to increased production and sales[11] Government Support and Future Plans - The company received government subsidies amounting to ¥8,936,317.68, which contributed to other income increasing by 114.49%[11] - The company plans to continue expanding its production capabilities with investments in the "Nanning Production Base Phase II" and "Haikou Meian Children's Medicine Intelligent Manufacturing Base" projects[12] Financial Reporting - There are no significant changes in the audit opinion type, indicating stability in financial reporting[17] - The company did not apply new accounting standards or interpretations for the first quarter of 2023, maintaining consistency in financial reporting[25] - The company’s cash flow management strategies appear to be evolving, as evidenced by the significant changes in cash inflows and outflows across various activities[24]

Financial Performance - The company's operating revenue for 2022 was CNY 1,515,046,453.62, representing an increase of 11.91% compared to CNY 1,353,793,179.98 in 2021[22]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 85,681,971.00, an increase of 18.78% from CNY 72,137,858.48 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 68,053,308.12, reflecting a significant increase of 34.96% compared to CNY 50,424,117.91 in 2021[22]. - The net cash flow from operating activities for 2022 was CNY 238,711,442.29, which is a substantial increase of 132.93% from CNY 102,483,892.77 in 2021[22]. - The net assets attributable to shareholders reached CNY 1,013,887,896.49, an increase of 9.23% compared to CNY 928,205,925.49 in the previous year[24]. - Total assets increased by 31.30% to CNY 2,312,057,375.26 from CNY 1,760,930,340.04 in the previous year[24]. - Basic earnings per share rose by 16.67% to CNY 0.21 from CNY 0.18 in the previous year[25]. - The weighted average return on equity increased by 0.96 percentage points to 8.82% from 7.86% in the previous year[25]. Dividend Policy - The company plans not to distribute cash dividends for 2022 due to significant cash expenditures exceeding 10% of the latest audited net assets, as it continues to invest in the Meian Children's Medicine Intelligent Manufacturing Base project[6][7]. - The company has no plans for capital reserve transfers or other forms of profit distribution in the near future, focusing instead on project investments[6][7]. Risk Management - The company has identified various risks in its future operations, which are detailed in the management discussion and analysis section of the report[10]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[9]. - The company has not reported any dissenting opinions from the supervisory board regarding risk management during the reporting period[186]. Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, as confirmed by the standard unqualified audit opinion from Ernst & Young Hua Ming[5]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements and effective governance[151]. - In 2022, the company held 4 shareholder meetings, 9 board meetings, and 6 supervisory meetings, demonstrating active governance practices[151]. - The company disclosed a total of 118 announcements on the Shanghai Stock Exchange in 2022, ensuring timely and accurate information dissemination[155]. - The company has established multiple channels for investor communication, including a dedicated investor relations section on its website[156]. Research and Development - The company has 120 products under research, with approximately 50% focused on pediatric medications, particularly in respiratory, digestive, and neurological treatment areas[34]. - The company's R&D expenses rose by 5.21% to CNY 105.66 million, reflecting a focus on new product development[73]. - Total R&D investment reached ¥138,341,942.67, accounting for 9.13% of operating revenue, with capitalized R&D making up 23.62% of total R&D[92]. - The company is actively engaged in R&D, with initiatives such as the establishment of research stations and partnerships to enhance its pharmaceutical development capabilities[47]. - The company is committed to enhancing its R&D capabilities, with multiple projects at different stages of development, including pharmacological and toxicological studies[113]. Market Strategy - The company aims to leverage the advantages of the Hainan Free Trade Port to enhance its pediatric medicine and traditional Chinese medicine development strategy[33]. - The company plans to optimize its business and product structure to strengthen its internal growth capabilities[33]. - The company is focused on sustainable development and innovation, aligning with national health policies and industry reforms to enhance its market position[42]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product offerings[163]. - The company is exploring market expansion opportunities through the development of new therapeutic areas, particularly in pediatric medicine[113]. Product Development - The company plans to expand its product offerings into high-end pediatric formulations, health foods, and medical devices, positioning itself to capitalize on new market trends[51]. - The company has obtained production licenses for five health food products, including calcium vitamin D granules and coenzyme Q10 soft capsules, enhancing its product offerings[55]. - The company is focusing on the development of innovative traditional Chinese medicine for pediatrics, enhancing its competitive edge in the market[111]. - The company is conducting clinical trials for multiple new products, including the pediatric cough syrup, which is currently in Phase II trials with the report writing in progress[113]. Sales and Marketing - The marketing system has been enhanced, resulting in steady growth in core operational indicators such as sales and collections, outperforming the industry average[35]. - The company has established a marketing network covering over 2,300 county-level markets and more than 24,000 public medical institutions[68]. - The company has formed strategic partnerships with over 30 leading chain pharmacies to enhance sales growth and community marketing efforts[69]. - The company is actively exploring new sales channels, including e-commerce and new media, to enhance brand outreach and user engagement[68]. Operational Efficiency - The company is committed to continuous improvement in production efficiency through lean manufacturing practices, aiming to reduce costs and enhance competitiveness[36]. - The company plans to implement cost reduction and efficiency enhancement through lean production practices across subsidiaries[139]. - The company has established a robust internal control management system in compliance with regulations, enhancing decision-making efficiency and ensuring asset safety[197]. Employee Management - The total number of employees across the parent company and major subsidiaries is 2,083, with 1,101 in the parent company and 982 in subsidiaries[187]. - The company has a competitive compensation system that includes salaries, bonuses, allowances, and social security, aimed at attracting and retaining talent[188]. - The company has conducted various training programs for new employees and management to enhance skills and compliance awareness[190]. Future Outlook - Future guidance indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by increased demand in key markets[162]. - The company aims to build the "first brand of children's medicine in China," with initiatives to promote children's health and safety in medication[64]. - The company plans to enhance marketing management and optimize sales channels to improve profitability as it continues to grow[123].